Pain Management

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

As medication experts, pharmacists can aid in treatment selection and support patients through the process.

Plaintiff argues that "blacklisting” certain individuals with opioid prescriptions was unlawful.

Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.

If approved, cyclobenzaprine hydrochloride (HCl) will be the first member of a new class of analgesic drugs for fibromyalgia.

In hospital and critical care settings, pharmacists can play a significant role in educating other health care providers about treatment options, proper dosing, and more.

GNSC-001 is a first-in-class gene therapy designed to offer long-term relief of musculoskeletal diseases such as osteoarthritis.

Pharmacists, who play a crucial role at the intersection of prescribing and dispensing, are well-positioned to influence these disparities.

Opioid stewardship pharmacist Maureen Saphire, PharmD, BCGP, focuses on advocating for appropriate opioid access for patients with cancer and sickle cell disease, promoting safe opioid use, and supporting leadership and strategic planning as keys to successful opioid stewardship.

Brian Anderson, PharmD, RPh provides important considerations for pharmacists regarding patient use of benzodiazepines.

Jeff Boyer, PharmD, BCPS, discusses his role in opioid stewardship at the Southern Arizona VA Healthcare System, highlighting his work in pain management coordination, interdisciplinary collaboration, patient and provider education, and data-driven strategies to support safe opioid use and address the opioid crisis.

Opioid stewardship coordinator Stephanie Abel, PharmD, BCPS, discusses initiatives such as increasing naloxone access, refining pain management protocols, and addressing stigma around opioid use disorder, highlighting the importance of clear goals and emotional intelligence for effective stewardship programs.

The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.

Had the pharmacy established safe opioid prescribing policies?

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

The updated recommendations include CGRP inhibitors as a first-line treatment option for chronic and episodic migraine prevention.

In previous studies, semaglutide was found to modulate dopamine reward signaling and decreased drug rewards (specifically heroin) in rodents.

Pharmacists have developed an expanded role in the team-based approach through medication therapy management.

The weight loss drug continues to show promise in treating a variety of other conditions.

The guidelines mark a shift in practice by recommending a multimodal approach to opioid prescribing practices.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The money could be used for prevention and treatment services, health care practitioner training, or other ways to stem the epidemic.

Pharmacists should educate patients about proper medication storage and offer naloxone to optimize safety.

AI and other technologies, in conjunction with ASHP’s guidelines, can improve drug diversion monitoring and outcomes.

Setting realistic goals can improve patients’ medication adherence and self-efficacy.

The injection adds an additional option to address emergency known or suspected opioid overdoses.

If approved, the drug would be the first in a new class of medications to treat acute pain in over 20 years.

The authors note they will continue to investigate treatments for patients with lupus as well as safe and effective methods of delivering these molecules to patients.

Pharmacists can prevent medication errors through knowledge, communication, and education

Results show that daily injections of buprenorphine over a 7-day period was safe and well-tolerated in patients who had Clinical Opioid Withdrawal Scale scores of 4 to 7.